Bleeding Disorders
From the Journals
Novel FVIII biomarker could help tailor hemophilia treatment
Patient-specific half maximal factor VIII effective concentrations measured using thromboelastography could help design a prophylaxis regimen.
Conference Coverage
Inhibitor risk nears zero after 75 days in previously untreated hemophilia A
PRAGUE – The researchers recommended frequent inhibitor testing until 75 days.
Conference Coverage
Hemophilia intracranial hemorrhage rates declining
PRAGUE – But patients with severe hemophilia face an increased risk of the complication.
From the Journals
Tranexamic acid shows improvements in heavy menstrual bleeding
Adolescents girls with heavy menstrual bleeding show significant improvements in quality of life with tranexamic acid.
News
FDA approves caplacizumab for aTTP
The injection is approved in combination with plasma exchange and immunosuppressive therapy for adults with acquired thrombotic thrombocytopenia...
From the Journals
Meta-analysis: IVIG bests anti-D on platelet count in pediatric ITP
But the clinical significance of this finding is unclear because of the lack of data on bleeding symptoms, according to authors of the meta-...
From the Journals
Turoctocog alfa appears safe, effective in reducing bleeds
The phase 3b open label trial included extended use of turoctocog alfa among males of all ages with severe hemophilia A.
Conference Coverage
Thrombin generation looks promising as a hemophilia biomarker
SAN DIEGO – Thrombin generation appears better able to differentiate between bleeding severities, compared with baseline factor activity.
Conference Coverage
Study identifies four patient subgroups in hemophilia A
SAN DIEGO – The Hemophilia Inhibitor PUP Study (HIPS) analyzed Factor VIII–specific antibodies in previously untreated infants with severe...
From the Journals
Impaired clot lysis associated with mild bleeding symptoms
Conference Coverage
Investigational gene therapy shows promise in hemophilia A
SAN DIEGO – Investigational SPK-8011 gene transfer therapy results in dose-dependent FVIII expression in patients with severe hemophilia A.